Biomarkers in CAR-T cell-related toxicities versus sepsis
| Biomarker | CAR-T cell toxicity (n=19) | Sepsis/Septic shock (n=21) | P value |
| sVCAM-1 (ng/mL) | 240±455 | 285±823 | 0.884 |
| sTNFRI (pg/mL) | 4243±3929 | 3520±4347 | 0.302 |
| TM (ng/mL) | 3496±2144 | 75±44 | <0.001* |
| ST2 (ng/mL) | 208±236 | 210±73 | 0.860 |
| Ang-2 (pg/mL) | 2841±3498 | 7696±12 043 | <0.001* |
| NETs (µg/mL) | 6±4 | 24±36 | <0.001* |
| sC5b9 (ng/mL) | 567±815 | 1219±912 | 0.001* |
| VWF:Ag (%) | 222±132 | 461±258 | <0.001* |
| A13 (%) | 74±25 | 15±24 | <0.001* |
| α2-AP (%) | 94±27 | 84±40 | 0.042* |
| PAI-1 Ag (ng/mL) | 38±38 | 119±93 | <0.001* |
Comparison between levels of biomarkers in patients with CAR-T cell-related toxicities at the onset of CRS/ICANS, before any specific treatment is administered (Tox-onset point) versus patient with sepsis/septic shock at their ICU admission. Values are expressed as median±IQR or percentage (as indicated).
*P<0.05.
A13, ADAMTS-13 activity; Ang-2, angiopoietin-2; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; NETs, neutrophil extracellular traps; PAI-1 Ag, inhibitor of the activator of plasminogen antigen; sC5b-9, soluble C5b-9; ST2, soluble suppression of tumorigenesis-2; sTNFRI, soluble TNF receptor 1; sVCAM-1, soluble vascular cell adhesion molecule 1; TM, thrombomodulin; VWF:Ag, von Willebrand factor antigen; α2-AP, α2-antiplasmin.